The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market is segmented across treatment type, diagnosis method, disease severity, patient demographics, distribution channel, end user, and geographic region. These segments help identify changing treatment preferences and emerging opportunities within the global CIDP healthcare landscape.

Treatment categories include intravenous immunoglobulin, plasmapheresis, corticosteroids, immunotherapy, and physical therapy. Intravenous immunoglobulin represents a significant treatment segment because of its established role in CIDP management. Immunotherapy is gaining increasing attention as researchers explore more targeted approaches.

Diagnosis methods include electromyography, nerve conduction studies, blood tests, lumbar puncture, and clinical evaluation. Electromyography currently represents an important diagnostic segment, while nerve conduction studies are also gaining adoption.

The market is further divided according to disease severity, including mild, moderate, severe, progressive, and relapsing conditions. Patient demographics can be evaluated by age group, gender, comorbidities, socioeconomic characteristics, and geographic distribution.

Distribution channels include hospitals, pharmacies, online pharmacies, and specialty clinics. End users include hospitals, research institutions, and homecare settings.

Regionally, North America maintains a leading position, while Europe and Asia-Pacific provide substantial opportunities for future market expansion. MRFR reports that North America accounted for more than 50% of global revenue in 2024, supported by advanced healthcare infrastructure and research activity.

These diverse segments demonstrate the evolving nature of the CIDP Market and highlight opportunities for companies developing innovative treatments and patient-focused healthcare solutions.